This drug, within the type of powder formulation, was earlier launched by Dr Reddy’s Laboratories in India, IICT stated in a launch. Under the phrases of the licence settlement, Anthem Biosciences Pvt Ltd, an built-in biopharmaceutical firm, will get non-exclusive licence for the method know-how for synthesis of 2-DG (2-Deoxy-D-Glucose), it stated.
“The agreement is in line with CSIR’s efforts to help people access various therapeutic options to combat COVID-19. CSIR labs have undertaken clinical trials of various repurposed drugs for the treatment of COVID-19,” stated Chandrasekhar, Director CSIR-IICT.
Anthem Biosciences Pvt Ltd is within the strategy of submitting an utility for getting the approval from DCGI in New Delhi and can subsequently manufacture and commercialise 2- DG from their services situated at Bommasandra, Bangalore and Harohalli, Kanakapura, Karnataka, the discharge stated.
Anthem Biosciences is within the forefront of engaged on area of interest and sophisticated biopharmaceuticals, Ajay Bhardwaj, CEO and Founder the corporate stated within the launch.
“We have hands-on experience in the development and manufacturing of prodrug of 2-DG API for a discovery research biopharmaceutical company from the USA. Because of our prior experience on 2-DG Prodrug, Post DCGI approval, we are geared up to supply multi-ton API to meet the immediate demand that might arise due to ongoing COVID-19 pandemic,” he stated.
“We have also developed domestic vendors for key raw materials for uninterrupted supplies to manufacture 2-DG API. Alternatively, we have developed an in-house process for key raw materials as we foresee the short supplies of these materials in coming months,” he added.